INVESTORS NEWSROOM RESPONSIBILITY LIVE HEALTHY CONSUMERS HEALTHCARE PROFESSIONALS CAREERS ABOUT ABBOTT HOME NEWSROOM PRESS RELEASES PRESS RELEASES BUSINESS CITIZENSHIP FINANCIAL INNOVATION PRODUCT RECOGNITION VIEW ALL 2021 ARCHIVE 2020 ARCHIVE 2019 ARCHIVE Nov 16, 2021 ABBOTT LAUNCHES SIMILAC® 360 TOTAL CARE® WITH EXCLUSIVE BLEND OF FIVE HMO PREBIOTICS AND DESIGNED TO SUPPORT THE IMMUNE SYSTEM, DIGESTIVE HEALTH AND BRAIN DEVELOPMENT - Similac® 360 Total Care® is the first and only infant formula with a blend of five different human milk oligosaccharides[1] (HMOs) across the three categories of HMOs in breast milk[2], the closest prebiotic blend to that of breast milk and previously only available to infants who are breastfed- Similac 360 Total Care with five HMOs is designed to support babies' developing immune system in the gut, where 70% of the immune system resides, promote digestive health and provide building blocks for babies' developing brains Nov 15, 2021 ABBOTT ACHIEVES HIGHEST SCORE IN ITS INDUSTRY FOR THE NINTH CONSECUTIVE YEAR ON THE DOW JONES SUSTAINABILITY INDEX (DJSI) - Abbott included on DJSI for 17 consecutive years for strong environmental, social and governance (ESG) performance- Top score in the Health Care Equipment & Supplies sector reflects Abbott's 2030 Sustainability Plan focus on innovating for greater access to life-changing technologies and breaking down barriers to health equity Nov 12, 2021 ABBOTT'S NEW LEADLESS PACEMAKER SYSTEM MEETS PRIMARY ENDPOINTS IN PIVOTAL TRIAL -- New, late-breaking data from the Leadless II IDE study confirm the Aveir™ leadless pacemaker achieved the pre-specified primary endpoints in treating patients with certain types of abnormal heart rhythms-- Abbott's Aveir system is the world's only leadless pacemaker specifically designed to be retrieved when the device needs to be replaced or if a patient's therapy needs to be changed-- Abbott's investigational Aveir leadless pacemaker is currently being evaluated for FDA approval Nov 10, 2021 NEW RESEARCH FINDS CHALLENGES IN SYMPTOM RECOGNITION AND DIAGNOSTIC TESTING CAN IMPACT PATIENT SATISFACTION FOR PEOPLE WITH VASCULAR DISEASE - One in four physicians surveyed feel the "lack of technology or equipment to make an accurate diagnosis of coronary artery disease and peripheral artery disease" is a key obstacle to an accurate diagnosis- Over a third of surveyed patients with Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD) described "confusion about what I was supposed to do next" as an important barrier to early and accurate diagnosis- Socioeconomic status, age and gender in underserved communities are contributing factors that impact patients’ access to care Nov 9, 2021 ABBOTT AND THE AMERICAN DIABETES ASSOCIATION® LAUNCH FIRST-OF-ITS-KIND COMMUNITY INITIATIVE IN COLUMBUS, OHIO, TO ADVANCE ACCESS TO DIABETES CARE AND TECHNOLOGY - First program to launch under American Diabetes Association's Health Equity Now™ platform- Community program seeks to understand how to increase access to health technology for underserved diabetes communities Nov 3, 2021 ABBOTT LAUNCHES NEW INITIATIVE TO DRIVE DIVERSITY IN MEDICAL RESEARCH AND IMPROVE CARE AMONG UNDER-REPRESENTED POPULATIONS - Abbott is addressing a key challenge to health equity by putting a greater focus on breaking down the barriers to clinical trial participation for under-represented groups- Company has dedicated $5 million for nearly 300 new scholarships over the next five years at medical schools at historically black colleges and universities (HBCU's) and minority nursing associations to support future generations of diverse clinical investigators- The company has also formed a new Diversity in Research Medical Advisory Board and dedicated funding to increase diversity enrollment within Abbott trials- The latest initiative is another step to support the work the company and its Foundation, the Abbott Fund, are doing to reduce health disparities around the world Oct 20, 2021 ABBOTT REPORTS THIRD-QUARTER 2021 RESULTS; ACHIEVES STRONG DOUBLE-DIGIT EARNINGS GROWTH AND RAISES GUIDANCE - Third-quarter sales growth of 23.4 percent; organic sales growth of 22.4 percent- GAAP diluted EPS from continuing operations growth of 69.6 percent; adjusted diluted EPS growth of 42.9 percent- Global COVID-19 testing-related sales were $1.9 billion in the third quarter- Excluding COVID-19 testing-related sales, third-quarter sales grew 11.7 percent on both a reported and organic basis compared to sales in 2019- Continues to strengthen portfolio with several new product approvals Oct 18, 2021 JASON SUDEIKIS JOINS ABBOTT, REAL MADRID AT NEW YORK STOCK EXCHANGE TO SUPPORT CHILDREN'S HEALTH Oct 18, 2021 ABBOTT AND REAL MADRID TEAM UP TO SUPPORT THE HEALTH AND NUTRITION OF CHILDREN GLOBALLY - Abbott becomes Health Sciences and Nutrition Partner of Real Madrid Football Club and Global Partner of the Real Madrid Foundation- Partnership will include support of the first men's and women's and Academy football teams as well as support of the Real Madrid Foundation- Foundation supports 65,000 children per year across 80 countries through education in sportsmanship, teamwork, respect, and health and nutrition- Partnership supports Abbott's commitment to address global malnutrition over the next decade Sep 30, 2021 ABBOTT COMMITS TO REDUCING MALNUTRITION GLOBALLY WITH LAUNCH OF ABBOTT CENTER FOR MALNUTRITION SOLUTIONS - Abbott is investing $45 million annually to help identify, treat and prevent malnutrition- Innovation hub will focus on reducing malnutrition for the most vulnerable populations in the world Sep 29, 2021 FDA APPROVES ABBOTT'S AMPLATZER™ TALISMAN™ SYSTEM FOR PFO CLOSURE IN PEOPLE AT RISK OF RECURRENT STROKE - Talisman system builds on the minimally invasive Amplatzer PFO Occluder, the world's leading patent foramen ovale (PFO) closure device that has been used to treat more than 180,000 patients worldwide- Abbott’s PFO closure technology helps to prevent blood clots from passing from the right to left side of the heart from where they can travel to the brain and cause a stroke- The Talisman system offers the industry's widest range of device sizes in the U.S. and the occluder comes pre-attached to the delivery cable, making the device easier for physicians to use Sep 28, 2021 REAL-WORLD DATA SHOW ABBOTT'S FREESTYLE LIBRELINK APP USERS SPEND MORE TIME IN TARGET GLUCOSE RANGE COMPARED TO READER USERS - People with diabetes who use the FreeStyle Libre mobile app experience clinically significant improved time in target range - Data reinforce the benefits of mobile apps, which can remotely connect people living with diabetes to healthcare professionals during COVID-19- Abbott is joining Novo Nordisk and The diaTribe Foundation in raising awareness and education on Time in Range Sep 23, 2021 ABBOTT HOSTS CONFERENCE CALL FOR THIRD-QUARTER EARNINGS Sep 22, 2021 FDA APPROVES ABBOTT'S EPIC™ PLUS TISSUE VALVES FOR PEOPLE IN NEED OF MITRAL OR AORTIC VALVE REPLACEMENT - New enhancements to Abbott's Epic valve – the most widely used mitral tissue heart valve in the U.S. and globally – can improve implantation and allow compatibility for future transcatheter valve procedures - Epic Plus designed to help patients with more complex cases of aortic or mitral regurgitation or stenosis - Latest device builds on history of surgical valve replacement as a reliable and critical therapy option for patients with valvular heart disease Sep 20, 2021 ABBOTT RECEIVES FDA APPROVAL FOR MINIMALLY INVASIVE PORTICO™ WITH FLEXNAV™ TAVR SYSTEM TO TREAT PATIENTS WITH AORTIC VALVE DISEASE - Transcatheter aortic valve replacement (TAVR) procedure treats people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery- With Portico approval, Abbott offers the industry's most comprehensive portfolio of structural heart solutions in the U.S. Sep 15, 2021 ABBOTT DECLARES 391ST CONSECUTIVE QUARTERLY DIVIDEND Sep 2, 2021 ABBOTT EXPANDS PERIPHERAL VASCULAR OFFERINGS WITH ACQUISITION OF WALK VASCULAR, LLC Acquisition builds upon Abbott's leading vascular portfolio, adding mechanical thrombectomy devices for treating patients with peripheral blood clots Aug 30, 2021 LATE-BREAKING DATA SHOWS ABBOTT'S AMPLATZER™ AMULET™ OCCLUDER OFFERS SUPERIOR LEFT ATRIAL APPENDAGE CLOSURE COMPARED TO WATCHMAN‡ DEVICE FOR PEOPLE WITH ATRIAL FIBRILLATION AT RISK OF STROKE - New data presented at ESC Congress 2021 and simultaneously published in Circulation show Amulet Occluder was superior in left atrial appendage (LAA) closure and noninferior on safety and effectiveness endpoints compared to Watchman device- Amulet device is the first and only minimally invasive option approved for LAA occlusion that does not require blood-thinning medication following implantation- Trial results supported recent FDA approval of Abbott's Amplatzer Amulet LAA Occluder to reduce the risk of stroke in patients with atrial fibrillation Aug 27, 2021 GUIDE-HF STUDY DATA SHOW ABBOTT'S CARDIOMEMS™ DEVICE CAN IMPROVE CARE FOR MORE PATIENTS WITH HEART FAILURE - The GUIDE-HF study examined the potential impact of Abbott's CardioMEMS™ HF System, a small implantable pulmonary pressure sensor, in an expanded patient population not currently approved for the device- Data from the GUIDE-HF trial suggests CardioMEMS can improve care for more types of patients battling heart failure and reduce hospitalizations, especially for patients suffering from earlier stages of the disease Aug 16, 2021 ABBOTT'S AMPLATZER™ AMULET™ DEVICE APPROVED BY FDA TO TREAT PEOPLE WITH ATRIAL FIBRILLATION AT RISK OF STROKE - Amulet is the first and only minimally invasive treatment option to offer immediate closure of the left atrial appendage (LAA), so blood-thinning medication isn't needed following implantation- The device helps to prevent blood clots from forming and leaving the LAA, reducing the risk of stroke in patients with atrial fibrillation, the most common sustained cardiac arrhythmia Aug 3, 2021 ABBOTT RECEIVES FDA CLEARANCE FOR ITS IMAGING TECHNOLOGY USING ARTIFICIAL INTELLIGENCE FOR VESSELS IN THE HEART - Ultreon™ 1.0 Software, the first-of-its-kind imaging software, merges optical coherence tomography with the power of automation using Artificial Intelligence- The new intuitive interface provides step-by-step guidance to enhance ease of use- When combined with Abbott's Dragonfly OpStar™ imaging catheter and PressureWire X™, the platform provides physicians with a comprehensive set of tools to provide better patient care Aug 2, 2021 ABBOTT'S FREESTYLE® LIBRE 2 IOS APP CLEARED IN U.S., PROVIDING A SEAMLESS DIGITAL EXPERIENCE TO SIMPLIFY DIABETES MANAGEMENT - FreeStyle Libre 2 iOS app is the only sensor-based glucose monitoring app that allows users to check their glucose with a compatible iPhone[1] every minute with optional real-time glucose alarms[2]- The FreeStyle Libre 2 app enables kids (ages 4 and older) and adults to easily share their glucose data with parents and other caregivers via the LibreLinkUp[3] app- Free to download on the App Store, the FreeStyle Libre 2 iOS app will be available soon Jul 29, 2021 ABBOTT INTRODUCES JOT DX™ INSERTABLE CARDIAC MONITOR, DESIGNED TO REDUCE DATA BURDEN AND IMPROVE ACCURATE DIAGNOSIS OF DIFFICULT-TO-DETECT ABNORMAL HEART RHYTHMS - Jot Dx™ Insertable Cardiac Monitor (ICM) expands Abbott's connected care portfolio and is the first and only device on the market with the option to control the amount of electronic data received for irregular heart rhythms, depending on the unique needs of the patient or clinic- Jot Dx™ ICM connects via Bluetooth with Abbott’s myMerlin™ mobile app for continuous remote monitoring, leading to a faster time to diagnosis compared to ICMs that may use traditional bedside monitors1- Abbott’s personalized concierge service, SyncUp™, provides one-on-one device setup support, helping patients connect Jot Dx™ ICM with the mobile app at home, taking the burden off physicians and clinic staff Jul 29, 2021 NEW STUDY: HALF OF AMERICANS LIVING WITH DIABETES MAY BE CONSUMING LESS THAN THE RECOMMENDED AMOUNT OF PROTEIN, WHICH IS ASSOCIATED WITH GREATER PHYSICAL LIMITATIONS - Patients with diabetes who did not meet the recommended daily intake of protein had greater physical limitations, which together may suggest an increased risk of muscle loss- Abbott's line of nutrition products scientifically designed for people with diabetes now includes Glucerna® 30g protein shakes to help people with diabetes meet important daily protein consumption goals Jul 22, 2021 ABBOTT REPORTS SECOND-QUARTER 2021 RESULTS - Sales growth of 39.5 percent; organic sales growth of 35.0 percent- GAAP diluted EPS from continuing operations growth of 120.0 percent; adjusted diluted EPS growth of 105.3 percent- Second-quarter sales, excluding COVID-19 testing-related sales, grew 12.3 percent on a reported basis and 11.3 percent on an organic basis compared to sales in 2019- Achieved strong sales growth across all four major business areas- Full-year forecast continues to reflect strong, double-digit EPS growth on both a GAAP and adjusted basis «123456789» CONSUMERS HEALTHCARE PROFESSIONALS CAREERS ABOUT ABBOTT SUBSCRIBE INVESTORS NEWSROOM RESPONSIBILITY LIVE HEALTHY PARTNERS CONTACTS SITE MAP POLICIES GLOBAL WEBSITES PRIVACY POLICY TERMS & CONDITIONS ADVERTISING PREFERENCES FOLLOW ABBOTT © 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details. Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.